Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,138,804
-
Total 13F shares
-
810,100
-
Share change
-
+699,243
-
Total reported value
-
$4,010,792
-
Price per share
-
$4.95
-
Number of holders
-
15
-
Value change
-
+$3,531,748
-
Number of buys
-
13
-
Number of sells
-
4
Institutional Holders of QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) as of Q3 2020
As of 30 Sep 2020,
QUALIGEN THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (QLGN) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
810,100 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC, Cetera Investment Advisers, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, JPMORGAN CHASE & CO, MORGAN STANLEY, and Retirement Group, LLC.
This page lists
15
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.